|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16.11.26 - 14:18
|
Ollin Biosciences and Its Next-Generation Medicines for Patients with Vision-Threatening Eye Diseases to be Acquired (Business Wire)
|
|
|
Lead program OLN324 is a next-generation, Phase 3 investigational, VEGF/Ang2 bispecific antibody being developed for diabetic macular edema and wet age-related macular degenerationAUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (“Ollin”), a privately-held clinical-stage biopharmaceutical company developing therapies for serious eye diseases, today announced it has entered into a definitive agreement to be acquired by Johnson & Johnson for $2.2 billion upfront with the potential for up to approximately $1.1 billion in additional regulatory and commercial milestone payments.
Ollin was founded in 2023 with a mission to identify and accelerate the development of next-generation therapies in ophthalmology. Ollin's lead program is OLN324, a Phase 3 investigational bispecific antibody designed to target VEGF and Ang2 with optimized molecular size and potency. OLN324 is being developed for wet AMD and diabetic macular edema, two serious retinal diseases affecting more than 40 million people worldwide...
|
|
|
16.11.26 - 14:06
|
Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology (Business Wire)
|
|
|
Acquisition adds OLN324, a Phase 3 investigational bispecific antibody for retinal vascular diseases, including wet AMD and diabetic macular edema
Accelerates Company's ambition to preserve, restore and enhance vision
Builds on Johnson & Johnson's long-standing presence as an innovator in vision
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced it has entered into a definitive agreement to acquire Ollin Biosciences, Inc., (“Ollin”) a clinical-stage biopharmaceutical company developing therapies for serious eye diseases, for $2.2 billion upfront, with the potential for additional regulatory and commercial milestone payments. Johnson & Johnson will also enter into a separate development funding agreement with Blackstone Life Sciences (“Blackstone”) to support the Phase 3 clinical advancement of OLN324, contingent upon acquisition close.
With this agreement, Johnson & Johnson would add to its pipeline OLN324, an investigational bispecific antibody designed to targe...
|
|
|
16.11.26 - 12:12
|
AMD Earnings: What Wall Street Missed (Fool)
|
|
|
AMD's latest earnings reveal a striking disconnect between business performance and investor expectations. See what's driving the sell-off and what could change the stock's direction....
|
|
|
|
|
|
|
15.11.26 - 18:18
|
AMD vs. Broadcom: With NVDA’s Jensen Huang Gone, Which AI Stock Wins the Most? (24/7 Wall St.)
|
|
|
Which AI chip stock belongs in a retirement-focused portfolio right now—AMD (NASDAQ:AMD) or Broadcom (NASDAQ:AVGO)—with Jensen Huang out at NVIDIA (NASDAQ:NVDA)? Huang resigned on November 12, 2026 after reports of personal misconduct and a board investigation, and CFO Colette Kress became interim CEO. AMD and Broadcom stock got a boost from Nvidia's loss, then both […]...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14.11.26 - 16:42
|
AMD Just Crushed Nvidia by 32 Points After Scandal. Here’s How NVDA Can Come Back (24/7 Wall St.)
|
|
|
AMD (NASDAQ:AMD) or NVIDIA (NASDAQ:NVDA): after one of the most lopsided weeks in the competition between these two chipmakers, how do they compare for investors building a retirement portfolio? The Kobeissi Letter called AMD's run its greatest five-session outperformance against Nvidia since Nvidia's 1999 IPO. On verified closing prices for the week ended November 13, […]...
|
|
|
|